Latest news with #MichaelDaniels
Malaysian Reserve
6 days ago
- Business
- Malaysian Reserve
NASDAQ: RCAT Lawsuit Alert: Investors who lost money with Red Cat Holdings, Inc. (NASDAQ: RCAT) shares should contact the Shareholders Foundation
SAN DIEGO, Aug. 12, 2025 /PRNewswire/ — The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Red Cat Holdings, Inc. (NASDAQ: RCAT). Investors who purchased shares of Red Cat Holdings, Inc. (NASDAQ: RCAT) prior to March 2022 and continue to hold any of those NASDAQ: RCAT shares, also have certain options and should contact the Shareholders Foundation at mail@ or call +1(858) 779 – 1554. On May 23, 2025, an investor in NASDAQ: RCAT shares filed a lawsuit against Red Cat Holdings, Inc. over alleged securities laws violations. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose that the Salt Lake City Facility's production capacity, and Defendants' progress in developing the same, was overstated, that the overall value of the SRR Contract was overstated, and that as a result, Defendants' public statements were materially false and misleading at all relevant times. Those who purchased shares of Red Cat Holdings, Inc. (NASDAQ: RCAT) should contact the Shareholders Foundation, Inc. CONTACT:Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 mail@ 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
Associated Press
16-07-2025
- Business
- Associated Press
Lawsuit Alert: Investors who lost money with Fortrea Holdings Inc. (NASDAQ: FTRE) should contact the Shareholders Foundation
SAN DIEGO, July 16, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Fortrea Holdings Inc. (NASDAQ: FTRE). Investors who purchased shares of Fortrea Holdings Inc. prior to July 2023 and continue to hold any of those NASDAQ: FTRE shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. On May 23, 2025, a NASDAQ: FTRE investor filed a lawsuit against Fortrea Holdings Inc. over alleged violations of securities laws. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose that Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings, that Fortrea overstated the cost savings it would likely achieve by exiting the TSAs, that as a result, the Company's previously announced EBITDA targets for 2025 were inflated, that accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times. Those who purchased shares of Fortrea Holdings Inc. (NASDAQ: FTRE) should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon. View original content to download multimedia: SOURCE Shareholders Foundation, Inc.
Malaysian Reserve
16-07-2025
- Business
- Malaysian Reserve
Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit
SAN DIEGO, July 16, 2025 /PRNewswire/ — Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) shares. Investors who purchased shares of Pacira BioSciences, Inc. prior to August 2023 and continue to hold any of those NASDAQ: PCRX shares also have certain options and contact the Shareholders Foundation at mail@ or call +1(858) 779 – 1554. On January 13, 2025, an investor in NASDAQ: PCRX shares filed a lawsuit over alleged violations of securities laws by Pacira BioSciences, Inc. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose that defendants created the false impression that Pacira had sufficient patent protections on Exparel, and as such, the ability to expand the marketing, production, and sales of Exparel, which Pacira stated was critical to its future growth and revenue, that Pacira knew that the '495 patent was not as protective as Pacira publicly touted because on June 6, 2023, the United States District Court for the District of New Jersey issued a ruling in eVenus Pharmaceutical Laboratories, Inc.'s favor regarding claims construction in another case filed by Pacira in a failed attempt to protect Exparel, and that therefore, when the '495 patent was invalidated in another case Pacira filed against eVenus, investors and analysts alike were shocked by the concerning news that Exparel, which accounts for approximately 80% of Pacira's revenue, did not have sufficient patent protection to prevent another company from producing a generic during the life of the patent. Those who purchased NASDAQ: PCRX shares should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 mail@ 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
Associated Press
30-04-2025
- Business
- Associated Press
Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation
SAN DIEGO, April 30, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Investors who purchased shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) prior to October 2022 and continue to hold any of those NYSE: ATNM shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. On March 27, 2025, a NYSE: ATNM investor filed a lawsuit against Actinium Pharmaceuticals, Inc. over alleged violations of securities laws. The plaintiff alleged that the Defendants failed to disclose that the Company's data from the Sierra Trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA, that the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate Sierra's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA, that as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved, and that as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Those who purchased shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon. View original content to download multimedia: SOURCE Shareholders Foundation, Inc.
Yahoo
02-04-2025
- Business
- Yahoo
Here's What Makes CACI International Inc (CACI) a Compelling Investment
River Road Asset Management, an investment management company released its 'River Road Mid Cap Value Fund' Q4 2024 investor letter. A copy of the letter can be downloaded here. In the fourth quarter, AMG River Road Small Cap Value Fund (Class N) returned 2.97% compared to -1.75% returns for the Russell MidCap Value Index. For the year 2024, the fund returned 13.56%, compared to Index return of 13.07%. Stocks rallied in November after a Republican victory but declined sharply following hawkish Fed comments. Shorter duration stocks, including small caps and value, lost most of their post-election gains by the end of December. For more information on the fund's best picks in 2024, please check its top five holdings. In its fourth quarter 2024 investor letter, River Road Mid Cap Value Fund emphasized stocks such as CACI International Inc (NYSE:CACI). CACI International Inc (NYSE:CACI) provides expertise and technology to enterprise and mission customers in support of national security in the intelligence, defense, and federal civilian sectors. The one-month return of CACI International Inc (NYSE:CACI) was 1.94%, and its shares gained 0.03% of their value over the last 52 weeks. On April 1, 2025, CACI International Inc (NYSE:CACI) stock closed at $369.90 per share with a market capitalization of $8.293 billion. River Road Mid Cap Value Fund stated the following regarding CACI International Inc (NYSE:CACI) in its Q4 2024 investor letter: "The largest new position added during the quarter was CACI International Inc (NYSE:CACI). CACI International Inc. (Cl A) (CACI) is a leading provider of expertise and technology services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. The Department of Defense accounts for 74% of revenues, with Federal Civilian Agencies contributing 21% and commercial customers the remaining 4%. In recent years, CACI has strategically shifted toward addressing complex technology challenges across the federal government while reducing its focus on basic professional services. Michael Daniels, former senior VP of SAIC, has served as chairman since January 2021, while John Mengucci has been president and CEO since June 2019. An IT technician in an open office with stacks of servers in the background. CACI International Inc (NYSE:CACI) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 48 hedge fund portfolios held CACI International Inc (NYSE:CACI) at the end of the fourth quarter compared to 38 in the third quarter. While we acknowledge the potential of CACI International Inc (NYSE:CACI) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. We covered CACI International Inc (NYSE:CACI) in another article, where we shared the list of worst performing IT services stocks to buy according to analysts. In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
